Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)

GENE - CHEMICAL INTERACTIONS REPORT

RGD ID: 69328
Species: Rattus norvegicus
RGD Object: Gene
Symbol: Cdkn1a
Name: cyclin-dependent kinase inhibitor 1A
Acc ID: CHEBI:28748
Term: doxorubicin
Definition: An anthracycline antibiotic that has formula C27H29NO11.
Chemical ID: MESH:D004317
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction is comprised of a complex set of reactions and/or regulatory events, possibly involving additional chemicals and/or gene products.
Object SymbolQualifierEvidenceWithReferenceSourceNotesOriginal Reference(s)
Cdkn1aaffects expressionEXP 6480464CTDDoxorubicin affects the expression of CDKN1A mRNAPMID:12187937
Cdkn1aincreases expressionEXP 6480464CTDDoxorubicin results in increased expression of CDKN1A mRNA; Doxorubicin results in increased expression of CDKN1A proteinPMID:15124910 PMID:18031568 PMID:27181935 PMID:32289291 PMID:38395252
Cdkn1amultiple interactionsEXP 6480464CTDFungal Polysaccharides inhibits the reaction [Doxorubicin results in increased expression of CDKN1A mRNA]; GW 6471 inhibits the reaction [SIRT6 protein inhibits the reaction [Doxorubicin results in increased expression of CDKN1A mRNA]]; SIRT6 protein inhibits the reaction [Doxorubicin results in increased expression of CDKN1A mRNA]PMID:27181935 PMID:38395252
Cdkn1aaffects expressionISOCDKN1A (Homo sapiens)6480464CTDDoxorubicin affects the expression of CDKN1A mRNA; Doxorubicin affects the expression of CDKN1A proteinPMID:17893511 PMID:25529476 PMID:31470548
Cdkn1aaffects response to substanceISOCDKN1A (Homo sapiens)6480464CTDCDKN1A affects the susceptibility to DoxorubicinPMID:15492826
Cdkn1adecreases expressionISOCDKN1A (Homo sapiens)6480464CTDDoxorubicin results in decreased expression of CDKN1A mRNA; Doxorubicin results in decreased expression of CDKN1A proteinPMID:14601052 PMID:38423379
Cdkn1adecreases response to substanceISOCdkn1a (Mus musculus)6480464CTDCDKN1A results in decreased susceptibility to DoxorubicinPMID:21920376
Cdkn1aincreases activityISOCDKN1A (Homo sapiens)6480464CTDDoxorubicin results in increased activity of CDKN1A proteinPMID:15141020
Cdkn1aincreases expressionISOCdkn1a (Mus musculus)6480464CTDDoxorubicin results in increased expression of CDKN1A mRNA; Doxorubicin results in increased expression of CDKN1A proteinPMID:16013437 PMID:16432175 PMID:16949053 PMID:21040762 PMID:21920376 PMID:22712078 PMID:24439385 PMID:25896364 PMID:28608983 PMID:28710503 PMID:36227756 PMID:38395252
Cdkn1aincreases expressionISOCDKN1A (Homo sapiens)6480464CTDDoxorubicin results in increased expression of CDKN1A; Doxorubicin results in increased expression of CDKN1A mRNA; Doxorubicin results in increased expression of CDKN1A proteinPMID:12006519 PMID:14665630 PMID:15205334 PMID:15555623 PMID:15601469 PMID:15781256 PMID:16439685 PMID:16537896 PMID:16705698 PMID:16857806 PMID:17653088 PMID:17682292 PMID:17974990 PMID:18347191 PMID:19074854 PMID:19351845 PMID:20346999 PMID:22927544 PMID:24816189 PMID:26025680 PMID:26320837 PMID:26969377 PMID:28507149 PMID:29803840 PMID:30258081 PMID:32562081 PMID:34719826 PMID:34783124 PMID:36634904 PMID:39427782
Cdkn1aincreases response to substanceISOCDKN1A (Homo sapiens)6480464CTDCDKN1A protein results in increased susceptibility to DoxorubicinPMID:15601469 PMID:22927544
Cdkn1amultiple interactionsISOCdkn1a (Mus musculus)6480464CTD[[MT1 protein co-treated with MT2 protein] affects the susceptibility to Doxorubicin] which affects the expression of CDKN1A mRNA; CDKN1A gene mutant form inhibits the reaction [Doxorubicin results in increased expression of ACTA2 protein]; CDKN1A gene mutant form inhibits the reaction [Doxorubicin results in increased expression of IFNG protein]; CDKN1A gene mutant form inhibits the reaction [Doxorubicin results in increased expression of IL6 mRNA]; CDKN1A gene mutant form inhibits the reaction [Doxorubicin results in increased expression of IL6 protein]; CDKN1A gene mutant form inhibits the reaction [Doxorubicin results in increased expression of NPPA mRNA]; CDKN1A gene mutant form inhibits the reaction [Doxorubicin results in increased expression of TNF protein]; Lovastatin inhibits the reaction [Doxorubicin results in increased expression of CDKN1A mRNA]; SIRT6 protein inhibits the reaction [Doxorubicin results in increased expression of CDKN1A mRNA]; TRP53 gene mutant form inhibits the reaction [Doxorubicin results in increased expression of CDKN1A mRNA]PMID:16013437 PMID:21040762 PMID:21920376 PMID:22712078 PMID:38395252
Cdkn1amultiple interactionsISOCDKN1A (Homo sapiens)6480464CTD1-phenyl-2-hexadecanoylamino-3-pyrrolidino-1-propanol inhibits the reaction [Doxorubicin results in increased expression of CDKN1A protein]; 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [Doxorubicin results in increased expression of CDKN1A protein]; 3-methyladenine inhibits the reaction [Doxorubicin results in increased expression of CDKN1A protein]; [dimethyl sulfone co-treated with Doxorubicin] affects the expression of CDKN1A mRNA; [Doxorubicin co-treated with Paclitaxel] results in increased expression of CDKN1A protein; [Doxorubicin co-treated with Resveratrol] results in increased expression of CDKN1A mRNA; [Doxorubicin co-treated with Resveratrol] results in increased expression of CDKN1A protein; [RELA protein affects the expression of CDKN1A protein] which affects the susceptibility to Doxorubicin; Acetylcysteine inhibits the reaction [Doxorubicin results in increased expression of CDKN1A protein]; bisphenol A affects the reaction [Doxorubicin affects the expression of CDKN1A mRNA]; bisphenol A inhibits the reaction [Doxorubicin results in increased expression of CDKN1A mRNA]; Caffeine inhibits the reaction [Doxorubicin results in increased expression of CDKN1A protein]; CDC25C protein inhibits the reaction [Doxorubicin results in increased expression of CDKN1A protein]; CDKN1A protein inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; CDKN1A protein results in decreased susceptibility to [Doxorubicin co-treated with TNF protein]; CGK 733 inhibits the reaction [Doxorubicin results in increased expression of CDKN1A protein]; Chloroquine inhibits the reaction [Doxorubicin results in increased expression of CDKN1A protein]; dimethyl sulfone affects the reaction [Doxorubicin results in increased expression of CDKN1A mRNA]; Doxorubicin affects the reaction [RELA protein binds to CDKN1A promoter]; Doxorubicin affects the reaction [RELA protein results in increased expression of CDKN1A mRNA]; Doxorubicin inhibits the reaction [KDM8 protein binds to CDKN1A promoter]; Doxorubicin promotes the reaction [TP53 protein binds to CDKN1A promoter]; Doxorubicin results in increased activity of and results in increased expression of CDKN1A protein; FHL2 protein affects the reaction [Doxorubicin results in increased expression of CDKN1A protein]; Fluorouracil promotes the reaction [[Doxorubicin co-treated with Paclitaxel] results in increased expression of CDKN1A protein]; ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of CDKN1A mRNA]; Glutathione inhibits the reaction [Doxorubicin results in increased expression of CDKN1A protein]; KDM8 protein affects the reaction [Doxorubicin results in increased expression of CDKN1A protein]; Loperamide promotes the reaction [Doxorubicin results in increased expression of CDKN1A mRNA]; nutlin 3 promotes the reaction [Doxorubicin results in increased activity of and results in increased expression of CDKN1A protein]; RV 538 inhibits the reaction [Doxorubicin results in increased expression of CDKN1A protein]; SPHK2 protein affects the reaction [Doxorubicin results in increased expression of CDKN1A protein]; tempol promotes the reaction [CDKN1A protein results in increased susceptibility to Doxorubicin]; TNF protein inhibits the reaction [Doxorubicin results in increased expression of CDKN1A protein]; TP53 affects the reaction [Doxorubicin results in increased activity of and results in increased expression of CDKN1A protein]; TP53 affects the reaction [nutlin 3 promotes the reaction [Doxorubicin results in increased activity of and results in increased expression of CDKN1A protein]]; TP53 gene mutant form inhibits the reaction [Doxorubicin results in increased expression of CDKN1A mRNA]; TP53 protein affects the reaction [Doxorubicin affects the reaction [RELA protein results in increased expression of CDKN1A mRNA]]; TP53 protein affects the reaction [Doxorubicin results in increased expression of CDKN1A mRNA]; TP53 protein affects the reaction [FHL2 protein affects the reaction [Doxorubicin results in increased expression of CDKN1A protein]]; TP53 protein mutant form affects the reaction [Doxorubicin results in increased expression of CDKN1A mRNA]; TRIM28 protein modified form inhibits the reaction [Doxorubicin results in increased expression of CDKN1A mRNA]; XAF1 protein affects the reaction [Doxorubicin results in increased expression of CDKN1A protein]PMID:15601469 PMID:15781256 PMID:15823547 PMID:16168113 PMID:16909308 PMID:17079232 PMID:17682292 PMID:17974990 PMID:18269916 PMID:18347191 PMID:19074854 PMID:19351845 PMID:21624110 PMID:22927544 PMID:24816189 PMID:26025680 PMID:26320837 PMID:26969377 PMID:28507149 PMID:30258081 PMID:31470548 PMID:32562081 PMID:34719826 PMID:34783124 PMID:39427782
Go Back to source page   Continue to Ontology report